Celsus Therapeutics Announces Pricing Of Public Offering And Listing On NASDAQ

Published: Jan 31, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK and LONDON, Jan. 30, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX) (formerly OTCQB:CLSXD), an emerging growth, development-stage biotech company, announced today the pricing of its public offering of 1,333,333 American Depository Shares ("ADSs") on the NASDAQ Capital Market at a price of $6.00 per ADS. Each ADS represents ten of the Company's ordinary shares. The gross proceeds from this offering, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $8,000,000. The offering is expected to close on or about February 5th, 2014, subject to customary closing conditions. Celsus also granted the underwriter a 30-day option to purchase 200,000 additional ADSs at the public offering price to cover over-allotments, if any.

Help employers find you! Check out all the jobs and post your resume.

Back to news